Stingray Therapeutics Patents – Insights & Stats (Updated 2023)

Stingray Therapeutics has a total of 32 patents globally, out of which 5 have been granted. Of these 32 patents, more than 75% patents are active. Europe (EPO) is where Stingray Therapeutics has filed the maximum number of patents, followed by United States of America and South Korea. Parallelly, the USA seems to be the main focused R&D center of Stingray Therapeutics and is also the origin country of the firm.

Stingray Therapeutics was founded in the year 2018 by Jonathan Northrup and Sunil Sharma. The company is a biotech firm that develops immunotherapies to treat various types of cancer.

Do read about some of the most popular patents of Stingray Therapeutics which have been covered by us in this article and also you can find Stingray Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Stingray Therapeutics patent portfolio.

How many patents does Stingray Therapeutics have?

Stingray Therapeutics has a total of 32 patents globally. These patents belong to 7 unique patent families. Out of 32 patents, 24 patents are active.

How Many Patents did Stingray Therapeutics File Every Year?

Stingray Therapeutics Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantStingray Therapeutics Applications FiledStingray Therapeutics Patents Granted
202231
2021181
202031
20193
20184
2017
2016
2015
2014
2013
2012
2011

How many Stingray Therapeutics patents are Alive/Dead?

Worldwide Patents

Stingray Therapeutics Patent Portfolio

How Many Patents did Stingray Therapeutics File in Different Countries?

Stingray Therapeutics Worldwide Patent Filing

Countries in which Stingray Therapeutics Filed Patents

CountryPatents
Europe6
United States Of America5
Korea (South)3
New Zealand1
Taiwan1
Canada1
Mexico1
Austria1
South Africa1
Australia1
Brazil1
Argentina1
Hong Kong (S.A.R.)1
Israel1

Where are Research Centres of Stingray Therapeutics Patents Located?

The R&D Centre of Stingray Therapeutics is in the US.

Most Cited Stingray Therapeutics Patent

US11407729B2 is the most popular patent in the Stingray Therapeutics portfolio. It has received 3 citations so far.

List of Stingray Therapeutics Patents

Stingray Therapeutics PatentsTitle
US11591313B2Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
US11407729B2Quinoline And Quinazoline Compounds And Methods Of Use Thereof
US11142524B2Substituted-3H-Imidazo[4,5-C]Pyridine And 1H-Pyrrolo[2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics
US10689376B2Substituted-3H-Imidazo [4,5-C] Pyridine And 1H-Pyrrolo[2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics
US20230183212A1Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
EP3658138B1Substituted-3H-Imidazo(4,5-C)Pyridine And 1H-Pyrrolo(2,3-C)Pyridine Series Of Novel Ectonucleotide Pyrophsphatase/Phosphodiestrase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulator As Cancer Immunotherapeutics
EP4259148A1Phosphonates As Inhibitors Of Enpp1 And Cdnp
EP4255425A1Imidazole Compounds As Inhibitors Of Enpp1
EP4100394A1Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
EP3941459A4Quinoline And Quinazoline Compounds And Methods Of Use Thereof
EP3829561A4Substituted-3H-Imidazo[4,5-C]Pyridine And 1H Pyrrolo[2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics
CA3166485A1Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
AU2021217148A1Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
IL295257AInhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
HK40077501AInhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
KR1020230118883AImidazole Compounds As Enpp1 Inhibitors
KR1020230118602APhosphonates As Inhibitors Of Enpp1 And Cdnp
MX2022009534AEctonucleotide Pyrophosphatase/Phosphophiesterase 1 (Enpp1) Inhibitors And Methods Of Use Thereof
KR1020220138399AInhibitors Of The Exonucleotide Pyrofospatase/Pospodi Esterase 1 (Enpp1) And How To Use It
BR112022014981A2Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) Inhibitors And Methods Of Use Thereof
ZA202208541AInhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
AR121269A1Ectonucleotide Pyrophosphatase / Phosphodiesterase 1 (Enpp1) Inhibitors And Methods Of Use Thereof
TW202140439AInhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
NZ790825AInhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
AT1561116TSubstituierte-3H-Imidazo(4,5-C)Pyridin- Und -1H-Pyrrolo(2,3-C)Pyridin-Reihen Von Neuartigen Ectonukleotid-Pyrophsphatase/Phosphodiestrase-1 (Enpp1) Und Stimulator Für Modulator Von Interferon-Genen (Sting) Als Krebsimmuntherapeutika
WO2022125613A1Phosphonates As Inhibitors Of Enpp1 And Cdnp
WO2022125614A1Phosphonates As Inhibitors Of Enpp1 And Cdnp
WO2022119928A1Imidazole Compounds As Inhibitors Of Enpp1
WO2021158829A1Inhibitors Of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (Enpp1) And Methods Of Use Thereof
WO2020190912A1Quinoline And Quinazoline Compounds And Methods Of Use Thereof
WO2019023635A8Substituted-3H-Imidazo(4,5-C)Pyridine And 1H-Pyrrolo(2,3-C)Pyridine Series Of Novel Ectonucleotide Pyrophsphatase/Phosphodiestrase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulator As Cancer Immunotherapeutics
WO2020028724A1Substituted-3 H-Imidazo[ 4,5-C]Pyridine And 1 H-Pyrrolo[ 2,3-C]Pyridine Series Of Novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (Enpp1) And Stimulator For Interferon Genes (Sting) Modulators As Cancer Immunotherapeutics

What are Stingray Therapeutics’ key innovation segments?

What Technologies are Covered by Stingray Therapeutics?

The chart below distributes patents filed by Stingray Therapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Stingray Therapeutics thinks it’s important to protect particular technology inventions.

R&D Focus: How has Stingray Therapeutics’ search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Stingray Therapeutics?

Related Articles

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.